Stanley L. Gaul

1.2k total citations
24 papers, 871 citations indexed

About

Stanley L. Gaul is a scholar working on Molecular Biology, Hematology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Stanley L. Gaul has authored 24 papers receiving a total of 871 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Hematology and 6 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Stanley L. Gaul's work include Platelet Disorders and Treatments (7 papers), Heparin-Induced Thrombocytopenia and Thrombosis (4 papers) and Neuroscience and Neuropharmacology Research (4 papers). Stanley L. Gaul is often cited by papers focused on Platelet Disorders and Treatments (7 papers), Heparin-Induced Thrombocytopenia and Thrombosis (4 papers) and Neuroscience and Neuropharmacology Research (4 papers). Stanley L. Gaul collaborates with scholars based in United States. Stanley L. Gaul's co-authors include David D. Wood, Walfred S. Saari, Rodney A. Bednar, J C Quintero, J. M. HOFFMAN, William A. Schleif, Mark E. Goldman, Jack H. Nunberg, John Wai and J A O'Brien and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Immunology and Biochemistry.

In The Last Decade

Stanley L. Gaul

24 papers receiving 813 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stanley L. Gaul United States	16	242	239	216	213	116	24	871
Odalys Gonzalez Paz Italy	17	138 0.6×	359 1.5×	90 0.4×	116 0.5×	16 0.1×	20	803
Eliane Coëffier France	16	30 0.1×	245 1.0×	101 0.5×	47 0.2×	81 0.7×	27	733
David R. Borcherding United States	19	216 0.9×	600 2.5×	38 0.2×	680 3.2×	30 0.3×	29	1.5k
R. F. NUTT United States	12	49 0.2×	499 2.1×	47 0.2×	65 0.3×	49 0.4×	22	935
Girija Krishnamurthy United States	14	107 0.4×	205 0.9×	20 0.1×	186 0.9×	45 0.4×	17	661
James W. Darnowski United States	17	145 0.6×	722 3.0×	37 0.2×	69 0.3×	34 0.3×	31	1.1k
Margaret E. Olson United States	19	42 0.2×	384 1.6×	52 0.2×	78 0.4×	11 0.1×	32	797
James M. Fujitaki United States	18	238 1.0×	585 2.4×	43 0.2×	132 0.6×	8 0.1×	34	1.2k
Nicos Karasavvas United States	15	70 0.3×	288 1.2×	206 1.0×	30 0.1×	33 0.3×	26	799

Countries citing papers authored by Stanley L. Gaul

Since Specialization

Citations

This map shows the geographic impact of Stanley L. Gaul's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stanley L. Gaul with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stanley L. Gaul more than expected).

Fields of papers citing papers by Stanley L. Gaul

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stanley L. Gaul. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stanley L. Gaul. The network helps show where Stanley L. Gaul may publish in the future.

Co-authorship network of co-authors of Stanley L. Gaul

This figure shows the co-authorship network connecting the top 25 collaborators of Stanley L. Gaul. A scholar is included among the top collaborators of Stanley L. Gaul based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stanley L. Gaul. Stanley L. Gaul is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Garner, Rachel M., Shobha Gopalakrishnan, John A. McCauley, et al.. (2015). Preclinical pharmacology and pharmacokinetics of CERC‐301, a GluN2B‐selectiveN‐methyl‐D‐aspartate receptor antagonist. Pharmacology Research & Perspectives. 3(6). e00198–e00198. 37 indexed citations

2.

McIntyre, Charles, John A. McCauley, Bohumil Bednář, et al.. (2009). Synthesis and evaluation of novel tricyclic benzo[4.5]cyclohepta[1.2]pyridine derivatives as NMDA/NR2B antagonists. Bioorganic & Medicinal Chemistry Letters. 19(17). 5132–5135. 6 indexed citations

3.

Nguyen, Kevin T., Christopher F. Claiborne, John A. McCauley, et al.. (2007). Cyclic benzamidines as orally efficacious NR2B-selective NMDA receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 17(14). 3997–4000. 19 indexed citations

4.

Mosser, Scott D., Stanley L. Gaul, Bohumil Bednář, et al.. (2003). Automation of In Vitro Dose-Inhibition Assays Utilizing the Tecan Genesis and an Integrated Software Package to Support the Drug Discovery Process. JALA Journal of the Association for Laboratory Automation. 8(4). 54–63. 1 indexed citations

5.

Nantermet, Philippe G., James C. Barrow, G. F. Lundell, et al.. (2002). Discovery of a nonpeptidic small molecule antagonist of the human platelet thrombin receptor (PAR-1). Bioorganic & Medicinal Chemistry Letters. 12(3). 319–323. 32 indexed citations

6.

Barrow, James C., Philippe G. Nantermet, Harold G. Selnick, et al.. (2001). Discovery and initial structure–Activity relationships of trisubstituted ureas as thrombin receptor (PAR-1) antagonists. Bioorganic & Medicinal Chemistry Letters. 11(20). 2691–2696. 17 indexed citations

7.

Egbertson, Melissa S., Jacquelynn J. Cook, Bohumil Bednář, et al.. (1999). Non-Peptide GPIIb/IIIa Inhibitors. 20. Centrally Constrained Thienothiophene α-Sulfonamides Are Potent, Long Acting in Vivo Inhibitors of Platelet Aggregation. Journal of Medicinal Chemistry. 42(13). 2409–2421. 41 indexed citations

8.

Egbertson, Melissa S., Jacquelynn J. Cook, Bohumil Bednář, et al.. (1999). Non-Peptide GPIIb/IIIa Inhibitors. 20. Centrally Constrained Thienothiophene α-Sulfonamides Are Potent, Long Acting in Vivo Inhibitors of Platelet Aggregation. Journal of Medicinal Chemistry. 42(19). 4014–4014. 2 indexed citations

9.

Bednar, Rodney A., Stanley L. Gaul, Melissa S. Egbertson, et al.. (1998). Identification of Low Molecular Weight GP IIb/IIIa Antagonists That Bind Preferentially to Activated Platelets. Journal of Pharmacology and Experimental Therapeutics. 285(3). 1317–1326. 40 indexed citations

10.

Prugh, John D., Robert J. Gould, Robert J. Lynch, et al.. (1997). Nonpeptide GPIIB/IIIA inhibitors. 16. Thieno[2,3-b]thiophene α-sulfonamides are potent inhibitors of platelet aggregation. Bioorganic & Medicinal Chemistry Letters. 7(7). 865–870. 9 indexed citations

11.

Bednar, Rodney A., Bohumil Bednář, David A. Claremon, et al.. (1997). Non-Peptide Glycoprotein IIb/IIIa Inhibitors. 17. Design and Synthesis of Orally Active, Long-Acting Non-Peptide Fibrinogen Receptor Antagonists. Journal of Medicinal Chemistry. 40(12). 1779–1788. 49 indexed citations

12.

Gaul, Stanley L., David A. Claremon, David C. Remy, et al.. (1994). Transglutaminase Inhibition by 2-[(2-Oxopropyl)thio]imidazolium Derivatives: Mechanism of Factor XIIIa Inactivation. Biochemistry. 33(33). 10109–10119. 91 indexed citations

13.

Waxman, Lloyd, et al.. (1994). Identification and Characterization of Endothelin Converting Activity from EAHY-926 Cells: Evidence for the Physiologically Relevant Human Enzyme. Archives of Biochemistry and Biophysics. 308(1). 240–253. 31 indexed citations

14.

Goldman, Mark E., Jack H. Nunberg, J A O'Brien, et al.. (1991). Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity.. Proceedings of the National Academy of Sciences. 88(15). 6863–6867. 256 indexed citations

15.

Saari, Walfred S., Wasyl Halczenko, David W. Cochran, et al.. (1984). 3-Hydroxy-.alpha.-methyltyrosine progenitors, synthesis and evaluation of some (2-oxo-1,3-dioxol-4-yl)methyl esters. Journal of Medicinal Chemistry. 27(6). 713–717. 39 indexed citations

16.

Gaul, Stanley L., Gregory E. Martin, & Charles S. Sweet. (1984). Comparative Effects of Enalapril, Enalaprilic Acid and Captopril in Blocking Angiotensin I-Induced Pressor and Dipsogenic Responses in Spontaneously Hypertensive Rats. Clinical and Experimental Hypertension Part A Theory and Practice. 6(6). 1187–1206. 10 indexed citations

17.

Sweet, Charles S., et al.. (1981). Relationship between angiotensin I blockade and antihypertensive properties of single doses of MK-421 and captopril in spontaneous and renal hypertensive rats. European Journal of Pharmacology. 76(2-3). 167–176. 35 indexed citations

18.

Sweet, Charles S. & Stanley L. Gaul. (1977). Antagonism of conditioned salivation in conscious dogs by antihypertensive drugs. Canadian Journal of Physiology and Pharmacology. 55(4). 968–971. 4 indexed citations

19.

Sweet, Charles S. & Stanley L. Gaul. (1975). Attenuation of hydrochlorothiazide-induced hypokalemia in dogs by a β-adrenergic blocking drug, timolol. European Journal of Pharmacology. 32(2). 370–374. 15 indexed citations

20.

Wood, David D. & Stanley L. Gaul. (1974). Enhancement of the Humoral Response of T Cell-Depleted Murine Spleens by a Factor Derived from Human Monocytes in Vitro. The Journal of Immunology. 113(3). 925–933. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact